Phase I Trial: NovoTTF-200M—Electromagnetic Therapy for Refractory Spinal Metastasis

This Phase I study at M.D. Anderson evaluates the safety of NovoTTF-200M and NovoTTF-200A devices delivering electromagnetic therapy alone or with standard treatment in patients with refractory spinal metastasis. Both non-surgical and surgical groups with no standard care options are included as the trial explores a novel approach to managing metastatic tumors.